Cite
HARVARD Citation
Felip, E. et al. (n.d.). 1O IMpower010: ctDNA status in patients (pts) with resected NSCLC who received adjuvant chemotherapy (chemo) followed by atezolizumab (atezo) or best supportive care (BSC). Immuno-oncology technology. p. . [Online].